Autumn Meeting – Interview with Dr. Ana Rodrigues
allautoe 0 GECP entrevista news reunião vídeo
Dr. Ana Rodrigues, oncologist and member of the Scientific Committee of the Lung Cancer Study Group (GECP), led the conference “New Drugs, New Toxicities,” highlighting the challenges of new therapies in the treatment of lung cancer.
Regarding the main differences between conventional medications and new therapies, the specialist cited the “higher incidence of cutaneous effects that negatively affect the quality of life of patients with prolonged survival, making their management a challenge.”
She also pointed to other relevant toxicities, such as “infusion toxicity, with many events in the first infusion, and a higher incidence of thromboembolic events.”
Dr. Ana Rodrigues emphasized the importance of training healthcare professionals in the detection and management of these toxicities, reinforcing that “it is essential to invest in the continuing education of teams, as well as in the literacy of patients and society in general.”